drugset / Trial / NCT02486042

Omega-3 Long Chain Polyunsaturated Fatty Acid (LCPUFA) Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity

NCT02486042 ↗

RandomizedParallel-groupSingle-blindPrevention

Summary

Retinopathy of prematurity (ROP) is a blinding disease affecting infants born prematurely. These infants do not have enough essential fatty acids to structurally support the retina, the nerve tissue in the eye which allows us to see. A recent study showed that giving omega-3 (n-3) fatty acids to these infants soon after birth made them less likely to need invasive treatments for eye disease. This research trial will give young infants born prematurely n-3 fish oil treatment and look at how this changes factors in the blood that promote disease. Detailed blood studies comparing infants with and without ROP will be performed and the infants will be followed over time to assess their eye development.

Timeline

Start
2014-03
Primary completion
2019-12
Completion
2019-12

Outcome

Mixed primary results

registry analysis (other test); Standard of Care (Standard Nutrition) vs Omegaven; p = 0.22; t-test, 2 sided NCT02486042 ↗

registry analysis (other test); Standard of Care (Standard Nutrition) vs Omegaven; p = 0.43; t-test, 2 sided NCT02486042 ↗

registry analysis (other test); Standard of Care (Standard Nutrition) vs Omegaven; p = 0.001; t-test, 2 sided NCT02486042 ↗

registry MEAN Standard of Care (Standard Nutrition): PPAR-gamma: 18.67 (Standard Deviation 3.64) delta Ct (amplification cycles) NCT02486042 ↗

registry MEAN Omegaven: PPAR-gamma: 7.31 (Standard Deviation 3.55) delta Ct (amplification cycles) NCT02486042 ↗

registry MEAN Standard of Care (Standard Nutrition): STAT3: 11.12 (Standard Deviation 2.80) delta Ct (amplification cycles) NCT02486042 ↗

registry MEAN Omegaven: STAT3: 4.66 (Standard Deviation 1.51) delta Ct (amplification cycles) NCT02486042 ↗

registry Therefore, a HIGHER delta Ct value corresponds to a LOWER gene expression of the gene of interest relative to control. NCT02486042 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Omegaven Other / unclassified — Intravenous